Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has dropped 2.2%, yet it is up 24% over the past year with earnings forecasted to grow by 15% annually. In such dynamic conditions, identifying high growth tech stocks involves looking for companies with robust innovation and strong potential to capitalize on emerging trends in technology.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	24.13%	24.28%	★★★★★★
Ardelyx	25.47%	69.63%	★★★★★★
Sarepta Therapeutics	24.09%	42.97%	★★★★★★
Alnylam Pharmaceuticals	22.34%	70.30%	★★★★★★
Clene	77.61%	59.19%	★★★★★★
TG Therapeutics	34.86%	56.98%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Travere Therapeutics	31.70%	72.51%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

BeiGene (NasdaqGS:BGNE)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BeiGene, Ltd. is an oncology company focused on discovering and developing cancer treatments for patients in the United States, China, Europe, and internationally, with a market cap of $18.75 billion.

Operations: BeiGene generates revenue primarily from its pharmaceutical products, amounting to CN¥23.51 billion. The company is focused on the oncology sector, operating across multiple regions including the United States, China, and Europe.

BeiGene, despite its current unprofitability, is poised for significant growth with an expected revenue increase of 19.2% annually, outpacing the US market's 9.1%. This robust forecast is underpinned by promising clinical advancements and strategic financial maneuvers, such as a recent $400 million credit facility aimed at bolstering operations. Notably, BeiGene's R&D commitment is evident in its pipeline developments like BRUKINSA and BGB-16673, which are making notable strides in chronic lymphocytic leukemia treatments. With earnings projected to surge by 73.34% annually and a strategy focused on high-risk patient populations, BeiGene’s integration of innovative therapies could redefine treatment standards in its sector.

• Take a closer look at BeiGene's potential here in our health report.

• Understand BeiGene's track record by examining our Past report.

Gilead Sciences (NasdaqGS:GILD)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines in areas of unmet medical needs across the United States, Europe, and internationally with a market cap of approximately $115.37 billion.

Operations: Gilead generates revenue primarily through the discovery, development, and commercialization of innovative medicines, amounting to $28.30 billion. The company operates in regions including the United States and Europe, addressing areas with unmet medical needs.

Gilead Sciences, despite a challenging backdrop with a one-off loss of $10.3 billion impacting its recent financials, has demonstrated resilience and strategic acumen through significant partnerships and product developments. The company's earnings are poised for robust growth, forecasted at 40.7% annually over the next three years, outstripping the US market's average of 15.2%. This growth trajectory is supported by strategic alliances like the recent collaboration with Terray Therapeutics to harness AI in drug discovery, reflecting Gilead’s commitment to integrating cutting-edge technologies for therapeutic advancements. Moreover, Gilead’s R&D dedication is underscored by an ongoing investment in innovative treatments such as seladelpar for PBC, which recently received positive opinions from European regulators and could enhance Gilead’s market presence upon final approval.

• Click here to discover the nuances of Gilead Sciences with our detailed analytical health report.

• Examine Gilead Sciences' past performance report to understand how it has performed in the past.

AbbVie (NYSE:ABBV)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacture, and sale of pharmaceuticals with a market cap of $310.27 billion.

Operations: The primary revenue stream for AbbVie comes from its Innovative Medicines and Therapies segment, generating $55.53 billion.

AbbVie's recent advancements in biopharmaceuticals underscore its strategic positioning in high-growth sectors, particularly with breakthrough therapies like epcoritamab for lymphoma and tavapadon for Parkinson's disease. These innovations not only highlight the company's robust pipeline but also its commitment to addressing complex medical needs, evidenced by a 100% overall response rate in one of its clinical trials. Financially, AbbVie has demonstrated resilience with an annualized revenue growth of 6.1% and earnings growth forecast at 28%, signaling strong future prospects despite a competitive landscape. This performance is supported by substantial R&D investments, ensuring sustained innovation and market presence.

• Navigate through the intricacies of AbbVie with our comprehensive health report here.

• Assess AbbVie's past performance with our detailed historical performance reports.

Taking Advantage

• Navigate through the entire inventory of 237 US High Growth Tech and AI Stocks here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com